Drug Price Trends for COMPLERA TABLET

Average Pharmacy Cost for COMPLERA TABLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
COMPLERA TABLET	61958-1101-01	130.14110	EACH	2026-06-17
COMPLERA TABLET	61958-1101-01	130.02928	EACH	2026-05-20
COMPLERA TABLET	61958-1101-01	130.51848	EACH	2026-01-01
COMPLERA TABLET	61958-1101-01	124.42181	EACH	2025-12-17

Market Analysis and Price Projections for COMPLERA Tablet

Last updated: February 16, 2026

Overview
COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is an antiretroviral therapy (ART) approved by the FDA in 2011 for the treatment of HIV-1 infection. It offers a once-daily, fixed-dose combination designed for treatment-naïve and experienced patients.

Market Landscape

Global HIV Treatment Market
The HIV treatment market exceeded $22 billion in 2022, with growth driven by rising HIV prevalence in regions such as sub-Saharan Africa, Asia-Pacific, and Latin America, alongside increasing access to ART. Key players include Gilead Sciences, ViiV Healthcare (a GlaxoSmithKline and Pfizer joint venture), and Merck.

Market Share of COMPLERA
COMPLERA held approximately 18% of the fixed-dose ART market in the U.S. in 2022, second to Biktarvy (Gilead). Its share is buoyed by its efficacy, once-daily dosing, and favorable side effect profile, but faces competition from other single-tablet regimens such as Biktarvy and Descovy.

Key Competitive Dynamics

• Pricing: COMPLERA's list price in the U.S. is approximately $3,400 per month.
• Market Penetration: Physicians favor regimens with proven efficacy and tolerability, leading to sustained demand, especially among treatment-naïve patients.
• Patents and Generic Entry: Patent exclusivity extends until 2027. Generic versions of tenofovir disoproxil fumarate are available, possibly influencing pricing and market share in jurisdictions outside the U.S.
• Regulatory & Policy Factors: Governments are shifting toward generic acceptance and price negotiations, impacting revenue potential.

Price Trajectory (Historical and Projected)

Year	Estimated Average Wholesale Price (AWP)	Comments
2022	$3,400/month	Current list price in the U.S.
2023	$3,200/month	Price slightly decreased due to negotiated discounts and market competition.
2024	$3,000/month	Anticipated decline driven by increased generic competition outside the U.S. and transparent pricing policies.
2025	$2,800/month	Price pressure from generic formulations and biosimilars in certain markets.
2026	$2,500/month	Continued decline as patent exclusivity lapses.

Factors Influencing Price Forecasts

• Patent Expiry: The core patents expire in 2027, opening markets to generics and biosimilars.
• Regulatory Approvals: Accelerated approvals of generics could lead to price discounts of 30-50% in targeted regions.
• Market Adoption: Physician prescribing habits and patient preferences influence dynamic pricing adjustments.
• Insurance & Reimbursement: U.S. Medicaid and private insurers negotiate discounts, affecting net pricing. International markets often have lower, regulated prices.

Forecast Assumptions

• The core patent holds until 2027, after which generics capture 80% of market share in key regions.
• Volume increases modestly at an annual rate of 3% due to increased testing and diagnosis.
• U.S. pricing remains relatively stable until patent expiry, with a 5-8% yearly reduction driven by market pressures.

Implications for Stakeholders

• Gilead’s revenue from COMPLERA is expected to decline steadily from 2024 onward, assuming patent expiration and generic entry.
• Price competition outside the U.S. will accelerate, impacting global revenue streams.
• The shift toward combination therapies with newer agents, like Biktarvy, may reduce COMPLERA’s outpatient prescriptions.

Strategic Considerations

• Gilead is directing investment towards next-generation therapies and long-acting injectable formulations to mitigate revenue declines.
• Expansion into emerging markets with lower price points remains critical for sustaining volume.

Summary
COMPLERA’s existing market and pricing structure face downward pressure from patent expiration, generic competition, and evolving treatment standards. Its current pricing of approximately $3,400 per month is poised to decline to around $2,500 by 2026 in the absence of new patent protections or formulations.

---

Key Takeaways

• COMPLERA maintains a significant share in the U.S. HIV treatment market with current prices near $3,400/month.
• Patent expiry in 2027 is expected to accelerate pricing declines, especially outside the U.S.
• Entry of generics will substantially reduce prices, potentially by 30-50% after patent expiry.
• Market growth is constrained by competition from newer regimens and better-tolerated formulations.
• Gilead compensates through pipeline diversification into long-acting therapies and innovative treatment modalities.

---

FAQs

1. How does patent expiration impact COMPLERA’s pricing?
Patent expiration allows generic manufacturers to enter the market, increasing competition and significantly reducing drug prices, often by 30-50% in the first few years post-expiry.

2. What are the main competitors to COMPLERA?
Biktarvy (Gilead), Descovy (Gilead), and other single-tablet regimens like Atripla and Triumeq are key competitors with similar or superior efficacy and tolerability profiles.

3. How will global pricing trends differ from the U.S.?
In emerging markets, pricing is generally lower due to government regulations, negotiations, and local manufacturing. Generic penetration occurs earlier, leading to faster price declines.

4. What role do new ART formulations play in the market?
Long-acting injectable therapies, such as Gilead’s Cabenuva, shift treatment paradigms and threaten traditional oral regimens’ market share, influencing overall pricing strategies.

5. What strategic responses could Gilead consider?
Gilead may focus on developing next-generation therapies, expanding access in emerging markets, and leveraging patent protections through formulation improvements.

---

Sources
[1] IQVIA, "Global HIV Therapeutics Market Report," 2022.
[2] Gilead Sciences Annual Reports, 2022-2023.
[3] FDA Drug Database, 2022.
[4] Gilead Corporate Website, "Long-Acting HIV Therapy Pipeline," 2023.
[5] MarketWatch, "HIV Treatment Market Outlook," March 2023.